Cargando…

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Detalles Bibliográficos
Autores principales:	Brochez, Lieve, Meireson, Annabel, Chevolet, Inès, Sundahl, Nora, Ost, Piet, Kruse, Vibeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062523/ https://www.ncbi.nlm.nih.gov/pubmed/30050132 http://dx.doi.org/10.1038/s41467-018-05047-1

Ejemplares similares

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
por: De Wolf, Katrien, et al.
Publicado: (2017)

Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
por: Meireson, Annabel, et al.
Publicado: (2021)

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma
por: Meireson, Annabel, et al.
Publicado: (2021)

Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
por: Meireson, Annabel, et al.
Publicado: (2018)

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial
por: Spaas, Mathieu, et al.
Publicado: (2021)

Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’
por: Jacquelot, Nicolas, et al.
Publicado: (2018)

IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
por: Sundahl, Nora, et al.
Publicado: (2017)

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
por: De Bock, Marlies, et al.
Publicado: (2018)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021)

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
por: Chevolet, Ines, et al.
Publicado: (2015)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Effects of radiation on the metastatic process
por: Sundahl, Nora, et al.
Publicado: (2018)

Long non-coding RNAs in cutaneous melanoma: clinical perspectives
por: Hulstaert, Eva, et al.
Publicado: (2017)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Impact of the COVID-19 Pandemic on the Incidence and Thickness of Cutaneous Melanoma in Belgium
por: Demaerel, Philip Georg, et al.
Publicado: (2023)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol
por: Rammant, Elke, et al.
Publicado: (2017)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

P-cadherin counteracts myosin II-B function: implications in melanoma progression
por: Jacobs, Koen, et al.
Publicado: (2010)

Development and validation of an m6A RNA methylation regulator-based signature for the prediction of prognosis and immunotherapy in cutaneous melanoma
por: Li, Tingting, et al.
Publicado: (2023)

Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
por: Adhoute, Xavier, et al.
Publicado: (2022)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Control of Respiratory Drive by Noninvasive Ventilation as an Early Predictor of Success
por: Spinelli, Elena, et al.
Publicado: (2020)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score
por: Schaule, Jana, et al.
Publicado: (2020)

Recent Advances and Challenges in Uveal Melanoma Immunotherapy
por: Fu, Yihang, et al.
Publicado: (2022)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score
por: Schaule, Jana, et al.
Publicado: (2020)

Reply to Comment on “Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy”
por: Santos, Inês P., et al.
Publicado: (2019)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Essential preanalytics in PD‐L1 immunocytochemistry
por: t Hart, Nils A, et al.
Publicado: (2018)

Metastatic Melanoma with an Unknown Primary
por: Babu, Anuradha Kakkanatt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7q4vqk8cu9u2oqtql1r55ogn7b